BioElectronics Corporation (OTC: BIEL) announced today the commercial launch of its ActiPatch device in Taiwan through its appointed distributor, Aphrodite Medical Group. This expansion marks a significant step in the company's strategy to bring non-invasive, drug-free pain therapy to new markets.
ActiPatch is a US FDA-cleared medical device that delivers pulsed shortwave therapy to modulate pain at the peripheral nerve level. Each device provides up to 720 hours of continuous therapy and can be worn during sleep, offering a patient-friendly alternative to traditional pain medications. The initial shipment of units has been completed, positioning the product for a coordinated market launch in Q2 2026, focusing initially on musculoskeletal pain management.
"The appointment of Aphrodite Medical Group establishes a strong commercial foundation for ActiPatch in Taiwan," said Kelly Whelan, CEO of BioElectronics Corporation. "Their clinical infrastructure and commitment to advanced patient care make them a capable partner to introduce and scale this therapy in a meaningful way."
Aphrodite Medical Group, a well-established healthcare provider in Taiwan with a broad clinical footprint, will lead market introduction, physician engagement, and patient access initiatives across its network and affiliated channels. "We are pleased to bring ActiPatch to Taiwan as part of our commitment to delivering innovative, patient-centered therapies," said Yang Pei-Hsien, Vice President of Aphrodite Medical Group. "This technology aligns with the growing demand for safe, effective, and drug-free pain management options."
The launch underscores BioElectronics' strategy to expand through high-quality distribution partnerships in key markets while maintaining focus on clinically validated, scalable bioelectronic therapies. The company's products, including ActiPatch and RecoveryRx, are FDA-cleared and use pulsed shortwave technology to treat pain and support recovery without drugs.
This move into Taiwan comes amid a global shift toward non-pharmacological pain management alternatives, driven by concerns over opioid addiction and side effects of long-term medication use. By offering a drug-free device that can be used continuously for up to 720 hours, ActiPatch addresses a growing need for safe, long-term pain relief options.
For more information, view the original release on NewMediaWire.
